CommercialCoverageMedium impact
08.02.37, Eladocagene exuparvovec-tneq (Kebilidi™)
Independence Blue Cross·Pharmacy, Genetics, Oncology·Pharmacy
Effective date
Nov 13, 2024
We identified it
Jun 19, 2026
Summary
This is a new pharmacy policy for Eladocagene exuparvovec-tneq (Kebilidi™), a gene therapy treatment effective November 13, 2024. The billing team must establish coverage, prior authorization, and billing procedures for this newly covered drug. Specific coverage criteria, billing codes, and authorization requirements should be reviewed in the full policy document.
Action Required
By November 13, 2024 (retroactively): Pharmacy and billing teams must review the complete policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=05&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-02-37 to identify specific HCPCS J-codes for Kebilidi™. Update billing system to recognize and process claims for this new gene therapy. Establish prior authorization requirements and workflow in the authorization system. Train billing and prior auth staff on coverage criteria, dosing, and documentation requirements. Verify patient eligibility and obtain required prior authorization before claim submission. Claims submitted without proper authorization may be denied.